Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells - implications for systemic control

Radiother Oncol. 2024 Jan 2:110077. doi: 10.1016/j.radonc.2023.110077. Online ahead of print.ABSTRACTThis exploratory study is a follow up to our previous investigation of immune response in the circulation of high-grade Gleason 9 prostate cancer patients treated with EBRT+BT compared to EBRT alone. Notably, EBRT+BT demonstrates the potential to elicit an effect on CD4/CD8 ratio which may attributed to improved clinical response to therapy. Our findings show promise for leveraging circulating immune cells as predictive biomarkers for radiotherapy response.PMID:38176656 | DOI:10.1016/j.radonc.2023.110077

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - January 4, 2024 Category: Radiology Authors: H Wang L Mendez G Morton A Loblaw H T Chung P Cheung A Mesci V Escueta T N Petchiny X Huang S D White M Downes D Vesprini S K Liu Source Type: research